Clinical Trial Goal
To find out:
- The highest dose of eganelisib that's safe to give
- If the combination of eganelisib and cytarabine is safe and works well to treat AML that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have AML that has relapsed or is refractory
- Have not had allogeneic (cells from a donor) or autologous (your own cells) blood or marrow transplant (BMT) in the last 6 months
- Are not being treated with immunosuppressants
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Cytarabine is a chemotherapy (chemo) drug that blocks the growth of cancer cells.
Eganelisib is a small molecule inhibitor that blocks phosphoinositide-3-kinase (PI3K)-y in certain cells.
You’ll get:
Eganelisib is a small molecule inhibitor that blocks phosphoinositide-3-kinase (PI3K)-y in certain cells.
You’ll get:
- Cytarabine – Given as intravenous (IV) infusions or as a shot under your skin. The dose you'll get depends on when you start the trial and how safe it has been
- Eganelisib – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has not yet approved eganelisib.
Locations
Sponsors
lead: Stelexis BioSciences
